Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christine de Vries - Scheidegger
Head of Market Development, Corporate R&D at Elsevier
About the author:
Christine has over 10 years of experience in the publishing industry working at Elsevier, with a focus on supporting Corporate R&D customers' needs with Elsevier's research intelligence solutions Scopus, SciVal and ScienceDirect. Her roles have involved delivering global product launches across industries such as Pharma and Life Sciences and she has commercial executive experience with real customer focus, market knowledge and business acumen. Prior to joining Elsevier, she worked as a management associate for GE Money. Christine holds a Bachelor of Science from Trinity University.
Posts by Christine de Vries - Scheidegger
Posted on June 12th, 2017 in Pharma R&D
It cannot be overstated how important it is for pharmaceutical companies to get new drugs to market as fast as possible. That some of these drugs could actually be life-saving, or at least life-altering, for hundreds, thousands or even millions of potential patients (more…)
Posted on May 5th, 2017 in Pharma R&D
In a recent case study featuring a mid-market biopharma company, a pre-clinical research leader explains that in order to avoid the risks of being wrong when investigating potential new molecules (more…)
Posted on January 18th, 2017 in Pharma R&D
Posted on August 17th, 2016 in Pharma R&D
“Last year, Vice President Biden said that with a new moonshot, America can cure cancer. Last month, he worked with this Congress to give scientists at the National Institutes of Health the strongest resources that they’ve had in over a decade. So tonight, I’m announcing a new national effort to get it done,” said President Obama in his final State of the Union address in January 2016.